

Iraq

COUNTRY GENERAL INFORMATION

Total population:	38 433 604
Gender F/M (%):	49.4 / 50.6
Population, age group <15 / ≥ 15 years (%):	38 / 62
Life expectancy at birth (F/M, years):	73 / 67
GDP (PPP int \$):	17 510
Income status:	Upper middle income
Number of 2 nd sub-national administrative level divisions, name:	148, District



EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	259	11 426	N/A	N/A
Number of relapses: ¹	No data	No data	N/A	N/A
Total number of cases:	259	11 426	N/A	N/A
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	47	44	N/A	N/A
Age group distribution (% , <5 / 5-14 / >14):	87 / 12 / 1	23 / 33 / 44	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.24	5.91	N/A	N/A
Number of endemic 2 nd sub-national administrative level divisions:	60	95	N/A	N/A
Population at risk (% , # at risk / total population): ²	28% 10 666 061 / 38 433 604	50% 19 326 809 / 38 433 604	N/A	N/A
Was there any outbreak?	No	No	N/A	N/A
Number of new foci: ³	No data	No data	N/A	N/A



Monthly distribution of new cases (January-December)

2018	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	30	41	46	32	15	12	18	7	8	11	10	8
CL	2 247	1 908	1 560	839	382	119	288	154	236	272	787	1 041

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and Incidence rate/10 000 at the national level from 2003 to 2018




¹ Relapse in this country is defined for CL as "incomplete epithelization of skin lesion" and for VL as "recurrence of VL symptoms with parasitological confirmation at any time point after initial cure"

² Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

³ Defined as "No definition available"

Disease distribution of new VL and CL cases at District level per 10 000 population (2018)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/UCN/NTD

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1997
Type of surveillance (CL / VL):	Vertical / Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin WG
Year latest national guidelines (CL / VL):	No data / No data
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities (CL / VL):	151 / 99

DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	No data	No data	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Sodium stibogluconate (SSG)

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL
Cases that completed treatment (% , # completed treatment / new cases):	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	No data	No data
Failure rate (% , # cases with treatment failure / new cases): ⁴	No data	No data
Case fatality rate (% , # cases who died / new cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴ Failure in this country is defined for CL as "persistence of recurrence during treatment or up to initial treatment outcome assessment" and for VL as "persistence of signs and symptoms or recurrence during treatment or up to initial treatment outcome assessment"